Adamas Pharma (ADMS) Misses Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
Adamas Reports Fourth Quarter and Full Year 2020 Financial Results
February 23, 2021 4:03 PM ESTFourth Quarter 2020 total revenues of $21.0 million, a 29% increase over fourth quarter 2019
Full Year 2020 total revenues of $74.5 million, a 36% increase over 2019
Second indication received February 2021 for GOCOVRI as an adjunctive treatment to levodopa/carbidopa in Parkinsons disease patients experiencing OFF episodes
EMERYVILLE, Calif.--(BUSINESS WIRE)-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the fourth quarter and full year ended... More
